Vertex Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Vertex Pharmaceuticals has a total shareholder equity of $18.5B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $23.9B and $5.4B respectively. Vertex Pharmaceuticals's EBIT is $4.4B making its interest coverage ratio -7. It has cash and short-term investments of $10.2B.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | -7x |
Cash | US$10.17b |
Equity | US$18.55b |
Total liabilities | US$5.37b |
Total assets | US$23.92b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: VRTX34's short term assets ($13.3B) exceed its short term liabilities ($3.8B).
Long Term Liabilities: VRTX34's short term assets ($13.3B) exceed its long term liabilities ($1.6B).
Debt to Equity History and Analysis
Debt Level: VRTX34 is debt free.
Reducing Debt: VRTX34 had no debt 5 years ago.
Debt Coverage: VRTX34 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: VRTX34 has no debt, therefore coverage of interest payments is not a concern.